Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.

Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, Levine BL, June CH, Emerson SG, Porter DL.

Am J Hematol. 2016 May;91(5):453-60. doi: 10.1002/ajh.24303. Epub 2016 Apr 4.

2.

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.

Chong EA, Ahmadi T, Aqui NA, Svoboda J, Nasta SD, Mato AR, Walsh KM, Schuster SJ.

Clin Cancer Res. 2015 Apr 15;21(8):1835-42. doi: 10.1158/1078-0432.CCR-14-2221. Epub 2015 Jan 28.

3.

Role of therapeutic apheresis in infectious and inflammatory diseases: Current knowledge and unanswered questions.

Sloan SR, Andrzejewski C Jr, Aqui NA, Kiss JE, Krause PJ, Park YA.

J Clin Apher. 2015 Oct;30(5):259-64. doi: 10.1002/jca.21370. Epub 2014 Oct 29. Review.

PMID:
25351167
4.

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH.

Clin Cancer Res. 2014 Mar 1;20(5):1355-65. doi: 10.1158/1078-0432.CCR-13-2817. Epub 2014 Feb 11.

5.

Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.

Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ.

Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7.

6.

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.

Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH.

Sci Transl Med. 2012 May 16;4(134):134ra62. doi: 10.1126/scitranslmed.3003330.

7.

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH.

Blood. 2011 Jan 20;117(3):788-97. doi: 10.1182/blood-2010-08-299396. Epub 2010 Oct 28.

8.

Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R, Mangan PA, Chew A, Veloso EA, Levine BL, Vonderheide RH, Jawad AF, June CH, Sullivan KE.

Blood. 2011 Jan 6;117(1):63-71. doi: 10.1182/blood-2010-07-296822. Epub 2010 Sep 23.

9.

Survivin as a universal tumor antigen for novel cancer immunotherapy: functions of a killer clone.

Aqui NA, Vonderheide RH.

Cancer Biol Ther. 2008 Dec;7(12):1888-9. No abstract available.

PMID:
19158476
10.

Adoptive immunotherapy: good habits instilled at youth have long-term benefits.

Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ Jr, Levine BL, Carroll RG, Riley JL, June CH.

Immunol Res. 2008;42(1-3):182-96. doi: 10.1007/s12026-008-8070-9. Review.

11.

Post-transplant adoptive T-cell immunotherapy.

Aqui NA, June CH.

Best Pract Res Clin Haematol. 2008 Sep;21(3):503-19. doi: 10.1016/j.beha.2008.07.001. Review.

12.

CD28 costimulation is essential for human T regulatory expansion and function.

Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, Liu R, Balcarcel RR, Fisher N, Levine BL, Carroll RG, Warner N, Blazar BR, June CH, Riley JL.

J Immunol. 2008 Aug 15;181(4):2855-68.

13.

Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, Carroll RG, Riley JL, June CH.

Mol Ther. 2007 May;15(5):981-8. Epub 2007 Mar 20.

14.

Treatment of PTLD with rituximab or chemotherapy.

Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE.

Am J Transplant. 2006 Mar;6(3):569-76.

15.

Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder.

Tsai DE, Aqui NA, Tomaszewski JE, Olthoff KM, Ahya VN, Kotloff RM, Bloom RD, Brozena SC, Hodinka RL, Stadtmauer EA, Schuster SJ, Nasta SD, Porter DL, Luger SM, Klumpp TR.

Clin Transplant. 2005 Oct;19(5):644-52.

PMID:
16146557
16.

Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene.

Tsai DE, Aqui NA, Vogl DT, Bloom RD, Schuster SJ, Nasta SD, Wasik MA.

Am J Transplant. 2005 Aug;5(8):2070-3.

17.

Use of serum protein electrophoresis to monitor patients with post-transplant lymphoproliferative disorder.

Aqui NA, Tomaszewski JE, Goodman D, Tsai DE.

Am J Transplant. 2003 Oct;3(10):1308-11.

18.

Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.

Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ.

J Clin Apher. 2003;18(2):51-4.

PMID:
12874815

Supplemental Content

Support Center